Niagen Bioscience (NAGE) director awarded options for 31,746 shares at $3.45 strike

Rhea-AI Filing Summary

Niagen Bioscience, Inc. director Ng Wang Yu Gary reported a compensation-related stock option grant. He received an option to acquire 31,746 shares of common stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036. Following this grant, he holds options for 31,746 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ng Wang Yu Gary

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	31,746	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 31,746 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 31,746 shares Exercise price: $3.45 per share Shares underlying option: 31,746 shares +3 more

6 metrics

Option shares granted 31,746 shares Stock option grant to director on June 24, 2026

Exercise price $3.45 per share Conversion or exercise price of stock option

Shares underlying option 31,746 shares Common stock underlying the derivative security

Total options after grant 31,746 shares Total derivative shares following transaction

Vesting date June 24, 2027 Option vests 100% on this date

Expiration date June 23, 2036 Option expiration

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, underlying security, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "3.4500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: "Common Stock""

vests 100% financial

"Option vests 100% on June 24, 2027."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 06:02 PM Accepted by SEC EDGAR 06/26/2026 - 06:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng Wang Yu Gary

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.45	06/24/2026		A		31,746		06/24/2027(1)	06/23/2036	Common Stock	31,746	$0	31,746	D

Explanation of Responses:

1. Option vests 100% on June 24, 2027.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Niagen Bioscience (NAGE) disclose?

Niagen Bioscience disclosed a stock option grant to director Ng Wang Yu Gary. He received options covering 31,746 common shares as compensation, with no cash purchase, providing future rights to buy shares at a fixed exercise price of $3.45 per share.

How many Niagen Bioscience (NAGE) shares are covered by the new option grant?

The new option grant covers 31,746 shares of Niagen Bioscience common stock. These shares are underlying a single stock option award and represent the director’s total option holdings reported following this transaction in the Form 4 filing.

What is the exercise price and term of the Niagen Bioscience (NAGE) option grant?

The option allows purchase of Niagen Bioscience common stock at an exercise price of $3.45 per share. It expires on June 23, 2036, giving the director a long-dated right to buy shares at that fixed price once vested.

When do the Niagen Bioscience (NAGE) options granted to Ng Wang Yu Gary vest?

The options granted to director Ng Wang Yu Gary vest 100% on June 24, 2027. Before that vesting date, the options generally cannot be exercised, so this award primarily represents future potential ownership rather than immediately exercisable rights.

Is the Niagen Bioscience (NAGE) Form 4 transaction a market purchase or sale?

The Form 4 reports a grant or award acquisition of stock options, not a market purchase or sale. The director did not buy or sell shares on the open market; instead, he received options as part of his compensation package.